Trial Profile
CD19-targeted CAR-T Cell Therapy for Minimal Residual Disease in B-cell Malignancies After Autologous Stem Cell Transplantation
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti-CD19 chimeric-antigen-receptor-T-cell-therapy-Yake-Biotechnology (Primary)
- Indications B-cell leukaemia; B-cell lymphoma; B-cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Cutaneous B-cell lymphoma; Diffuse large B cell lymphoma; Marginal zone B-cell lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 28 Jun 2018 New trial record